193 related articles for article (PubMed ID: 15815879)
1. Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
J Thromb Thrombolysis; 2004 Dec; 18(3):177-85. PubMed ID: 15815879
[TBL] [Abstract][Full Text] [Related]
2. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Clin Appl Thromb Hemost; 2004 Apr; 10(2):133-41. PubMed ID: 15094933
[TBL] [Abstract][Full Text] [Related]
3. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Diabetes Complications; 2003; 17(3):153-9. PubMed ID: 12738400
[TBL] [Abstract][Full Text] [Related]
4. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Hum Hypertens; 2002 Aug; 16(8):539-47. PubMed ID: 12149659
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
[TBL] [Abstract][Full Text] [Related]
6. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
[TBL] [Abstract][Full Text] [Related]
7. [Platelet activation marker].
Nomura S
Rinsho Byori; 2003 Nov; 51(11):1096-101. PubMed ID: 14679788
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Abdel-Zaher AO; Elkoussi AE; Abudahab LH; Elbakry MH; Elsayed EA
Fundam Clin Pharmacol; 2014 Jun; 28(3):237-48. PubMed ID: 23488690
[TBL] [Abstract][Full Text] [Related]
9. Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
J Hum Hypertens; 2005 Jul; 19(7):551-7. PubMed ID: 15829999
[TBL] [Abstract][Full Text] [Related]
10. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
Nomura S; Inami N; Iwasaka T; Liu Y
Platelets; 2004 May; 15(3):167-72. PubMed ID: 15203718
[TBL] [Abstract][Full Text] [Related]
11. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus.
Omoto S; Nomura S; Shouzu A; Nishikawa M; Fukuhara S; Iwasaka T
Diabetologia; 2002 Apr; 45(4):550-5. PubMed ID: 12032632
[TBL] [Abstract][Full Text] [Related]
12. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
[TBL] [Abstract][Full Text] [Related]
13. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Kang MH; Ahn TH; Choi IS; Shin EK
Circulation; 2004 Dec; 110(24):3687-92. PubMed ID: 15569835
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.
Yamada K; Hirayama T; Hasegawa Y
J Stroke Cerebrovasc Dis; 2007; 16(5):225-31. PubMed ID: 17845921
[TBL] [Abstract][Full Text] [Related]
15. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients.
Nadar S; Blann AD; Lip GY
Am J Hypertens; 2006 Sep; 19(9):970-7; discussion 978. PubMed ID: 16942942
[TBL] [Abstract][Full Text] [Related]
16. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
Pawelczyk M; Chmielewski H; Kaczorowska B; Przybyła M; Baj Z
Arch Med Sci; 2015 Mar; 11(1):115-21. PubMed ID: 25861297
[TBL] [Abstract][Full Text] [Related]
17. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy.
Omoto S; Nomura S; Shouzu A; Hayakawa T; Shimizu H; Miyake Y; Yonemoto T; Nishikawa M; Fukuhara S; Inada M
Nephron; 1999; 81(3):271-7. PubMed ID: 10050080
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
Schwieler JH; Kahan T; Wallén NH; Nussberger J; Hjemdahl P
J Hypertens; 2013 Aug; 31(8):1676-82. PubMed ID: 23625113
[TBL] [Abstract][Full Text] [Related]
19. Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.
Elseweidy MM; Elnagar GM; M Elsawy M; Ali AA; Zein N
J Pharm Pharmacol; 2020 Dec; 72(12):1812-1821. PubMed ID: 32880967
[TBL] [Abstract][Full Text] [Related]
20. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
Sato Y; Fujii S; Imagawa S; Ohmura K; Ohmura Y; Andoh Y; Dong J; Ishimori N; Furumoto T; Tsutsui H
J Atheroscler Thromb; 2007 Feb; 14(1):31-5. PubMed ID: 17332690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
